CLAIMS

1. Use of a bacterial strain belonging to the species *Bifidobacterium bifidum* identified as *Bifidobacterium bifidum* MIMBb23sg = BbfIBS01, wherein said bacterial strain was deposited at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) under deposit number DSM 32708 on 4 December 2017 by Sofar S.p.A. in the manufacture of a medicament for the treatment of or the prevention of gastrointestinal diseases, disorders or symptoms wherein the gastrointestinal diseases, disorders or symptoms are functional gastrointestinal disorders or inflammatory gastrointestinal disorders.

2. The use according to claim 1, wherein the functional gastrointestinal disorders are selected from: irritable bowel syndrome (IBS), dyspepsia, pyrosis, oesophagus, stomach and duodenum disorders, small intestinal bacterial overgrowth (SIBO), disorders with sub-inflammatory conditions.

3. The use according to claim 2, wherein the sub-inflammatory disorders are manifested in an elderly subject or celiac subject, or in a person suffering from diverticular disease.

4. The use according to claim 1, wherein the inflammatory gastrointestinal disorders or symptoms are selected from: Crohn's disease, ulcerative colitis, microscopic colitis, *Helicobacter pylori*, peptic or gastric ulcer, duodenal ulcer, celiac disease, diverticular disease and diverticulitis.

5. Use of a composition comprising:
a mixture comprising the bacterial strain *Bifidobacterium bifidum* MIMBb23sg = BbfIBS01 DSM 32708 according to claim 1,
and said composition comprises at least one food grade or pharmaceutical additive and/or excipient, in the manufacture of a medicament for the treatment of or prevention of gastrointestinal diseases, disorders or symptoms wherein the gastrointestinal diseases, disorders or symptom are functional gastrointestinal disorders or inflammatory gastrointestinal disorders.

6. The use according to claim 5, wherein said mixture comprises the bacterial strain *B. bifidum* MIMBb23sg = BbfIBS01 DSM 32708 at a concentration comprised in the range from $1x10^6$ CFU to $1x10^{12}$ CFU, with respect to a daily intake.

7. The use according to claim 6, wherein said mixture comprises the bacterial strain *B. bifidum* MIMBb23sg = BbfIBS01 DSM 32708 at a concentration comprised in the range from $1x10^7$ CFU to $1x10^{11}$ CFU, with respect to a daily intake.

8. The use according to claims 6-7, wherein said mixture comprises the bacterial strain *B. bifidum* MIMBb23sg = BbfIBS01 DSM 32708 at a concentration comprised in the range from $1x10^8$ CFU to $1x10^{10}$ CFU, with respect to a daily intake.

9. The use according to claim 5, wherein the functional gastrointestinal disorders are selected from: irritable bowel syndrome (IBS), dyspepsia, pyrosis, oesophagus, stomach and duodenum disorders, small intestinal bacterial overgrowth (SIBO), disorders with sub-inflammatory conditions, in an elderly subject or in a celiac subject, or in the diverticular disease.

10. The use according to claim 5, wherein the inflammatory gastrointestinal disorders or symptoms are selected from: Crohn's disease, ulcerative colitis, microscopic colitis, *Helicobacter pylori*, peptic or gastric ulcer, duodenal ulcer, celiac disease, diverticular disease and diverticulitis.